Review



arp 38942  (Aviva Systems)


Bioz Verified Symbol Aviva Systems is a verified supplier
Bioz Manufacturer Symbol Aviva Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 91

    Structured Review

    Aviva Systems arp 38942
    Arp 38942, supplied by Aviva Systems, used in various techniques. Bioz Stars score: 91/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/c+terminal+region/TARDBP+antibody+-+C-terminal+region+(ARP38942_T100)/pmc12922372-9-0-2
    Average 91 stars, based on 3 article reviews
    arp 38942 - by Bioz Stars, 2026-11
    91/100 stars

    Images

    Related Articles

    Cross-linking Immunoprecipitation:

    Article Title: Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43
    Article Snippet: .. nature neuroscience 1 Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43 Polymenidou M*, Lagier-Tourenne C*, Hutt KR*, Huelga SC, Moran J, Liang TY, Ling SC, Sun E, Wancewicz E, Mazur C, Kordasiewicz H, Sedaghat Y, Donohue JP, Shiue L, Bennett CF, Yeo GW and Cleveland DW Supplementary Figure 1 TDP-43 CLIP-seq method, reproducibility and saturation of binding sites. (a) Schematic representation of cross-linking, immunoprecipitation and high-throughput sequencing protocol (CLIP-seq). (b) Autoradiographs of CLIP-seq experiments performed in parallel using two different antibodies, a commercially available rabbit polyclonal TDP-43 antibody (Aviva Systems Biology, Cat. No. ARP38942_T100) left and an in-house monoclonal antibody recognizing an epitope within amino acids 251-414 of human TDP-4316. ..

    Binding Assay:

    Article Title: Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43
    Article Snippet: .. nature neuroscience 1 Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43 Polymenidou M*, Lagier-Tourenne C*, Hutt KR*, Huelga SC, Moran J, Liang TY, Ling SC, Sun E, Wancewicz E, Mazur C, Kordasiewicz H, Sedaghat Y, Donohue JP, Shiue L, Bennett CF, Yeo GW and Cleveland DW Supplementary Figure 1 TDP-43 CLIP-seq method, reproducibility and saturation of binding sites. (a) Schematic representation of cross-linking, immunoprecipitation and high-throughput sequencing protocol (CLIP-seq). (b) Autoradiographs of CLIP-seq experiments performed in parallel using two different antibodies, a commercially available rabbit polyclonal TDP-43 antibody (Aviva Systems Biology, Cat. No. ARP38942_T100) left and an in-house monoclonal antibody recognizing an epitope within amino acids 251-414 of human TDP-4316. ..

    Next-Generation Sequencing:

    Article Title: Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43
    Article Snippet: .. nature neuroscience 1 Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43 Polymenidou M*, Lagier-Tourenne C*, Hutt KR*, Huelga SC, Moran J, Liang TY, Ling SC, Sun E, Wancewicz E, Mazur C, Kordasiewicz H, Sedaghat Y, Donohue JP, Shiue L, Bennett CF, Yeo GW and Cleveland DW Supplementary Figure 1 TDP-43 CLIP-seq method, reproducibility and saturation of binding sites. (a) Schematic representation of cross-linking, immunoprecipitation and high-throughput sequencing protocol (CLIP-seq). (b) Autoradiographs of CLIP-seq experiments performed in parallel using two different antibodies, a commercially available rabbit polyclonal TDP-43 antibody (Aviva Systems Biology, Cat. No. ARP38942_T100) left and an in-house monoclonal antibody recognizing an epitope within amino acids 251-414 of human TDP-4316. ..

    other:

    Article Title: Impaired nucleocytoplasmic transport in SOD1-mediated ALS
    Article Snippet: ARP-38942 , Aviva Systems Biology , 1:500 , TDP-43, rabbit (for Fibroblasts).

    Article Title: Stress Granule Assembly Can Facilitate but Is Not Required for TDP-43 Cytoplasmic Aggregation
    Article Snippet: With a commonly used polyclonal antibody [ , ] (Proteintech, Rosemont, IL, USA, 10782-2-AP), we observed only very faint localization of TDP-43 to some SGs, with the vast majority of signal remaining nuclear.

    Article Title: Impaired nucleocytoplasmic transport in SOD1-mediated ALS.
    Article Snippet: Table.1 deleted IDENTIFIER SOURCE dilution Antibodies AB144P Merck Millipore 0.111111 Choline Acetyltransferase (ChAT), goat GTX113164 Genetex 0.388889 Choline Acetyltransferase (ChAT), rabbit MM-0070 Medi Mabs 0.111111 B8H10 (misfolded SOD1), mouse AR TIC LE IN PR ES S SC-28322 Santa-Cruz 0.111111 RanGAP1 (C-5), mouse SC-271376 Santa-Cruz 0.111111 Ran-GTP (a-7), mouse BLG-902901 Biolegend 0.180556 FG-Nups (mAB414), mouse SC-74454 Santa-Cruz 0.111111 XPO1 (C-1), mouse A300-469A Bethyl 0.11111 XPO1, rabbit 11701-1-AP Proteintech 0.180556 TDP-43, rabbit ARP-38942 Aviva Systems Biology 0.388889 TDP-43, rabbit (for Fibroblasts) Vim AvesLabs 0.388889 Vimentin, chicken AB5076 Abcam 0.319444 Ionized calcium-binding adaptor molecule 1 (Iba1), goat ABR-PA316727 Thermo 0.111111 GFAP, rabbit MABN140 Merck Millipore 0.180556 Neuronal nuclei antigen (Neun) AR TIC LE IN PR ES S SC28322 Santa-Cruz 1:100(in fibroblast)/1:250 (in postmortem tissue) RanGAP1, Mouse ab16048 Abcam 0.388889 Lamin B1, Rabbit sc-101523 Santa-Cruz 0.388889 SOD1(24), Mouse ab6046 Abcam 0.319444 β- tubulin, Rabbit ab178846 Abcam 0.319444 Iba1 46249 Cell Signaling Technology 0.180556 XPO1, Rabbit A31572 Thermo 0.284722 donkey anti-rabbit, Alexa fluor 555 A31570 Thermo 0.284722 donkey anti-mouse, Alexa fluor 555 A21443 Thermo 0.284722 Chicken anti-Rabbit, Alexa Fluor 647 AB-ab150111 Abcam 0.180556 Donkey anti-mouse, Alexa fluor 647 AB-ab150135 Abcam 0.180556 Donkey anti-goat , Alexa fluor 647 AR ICL E I N P RE SS 715-545-150 Jackson Immuno Research 0.388889 donkey anti-mouse, Alexa 488 A-21207 Invitrogen 0.388889 donkey anti-rabbit , Alexa 594 705-605-147 Jackson Immuno Research 0.388889 donkey anti-goat, Alexa 647 A21103 Invitrogen 0.736111 Goat anti-chicken, Alexa633 A10037 Thermo 0.25 Donkey anti-mouse Alexa Fluor 568 A32790 Thermo 0.25 Donkey anti rabbit Alexa Fluor 488 A21447 Thermo 0.25 Donkey anti goat Alexa Fluor 647 115-035-166 Jackson 3.513889 Goat anti-mouse HRP 111-035-144 Jackson 3.513889 Goat anti-rabbit HRP AR TIC LE IN PR ES S AR TIC LE IN PR ES S



    Similar Products

    91
    Aviva Systems pax7 rabbit polyclonal
    Pax7 Rabbit Polyclonal, supplied by Aviva Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/c+terminal+region/PAX7+Antibody+-+C-terminal+region+(ARP32742_P050)/pmc13752685-428-0-3
    Average 91 stars, based on 1 article reviews
    pax7 rabbit polyclonal - by Bioz Stars, 2026-11
    91/100 stars
      Buy from Supplier

    93
    Aviva Systems rabbit anti ank1
    Rabbit Anti Ank1, supplied by Aviva Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/c+terminal+region/ANK1+antibody+-+C-terminal+region+(ARP42566_T100)/10__1038_slash_s41467___026___78907___w-480-27-29
    Average 93 stars, based on 1 article reviews
    rabbit anti ank1 - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    95
    ECM Biosciences signals for murf1
    Maslinic acid modulates atrophy-related marker expression in palmitic acid-treated C2C12 myotubes. Differentiated C2C12 myotubes were treated with MA (0-10 μM) and then challenged with PA (0.4 mM) under lipotoxic stress conditions. (A) Protein expression of myosin IIa, <t>MuRF1,</t> and Atrogin-1 was determined by Western blot analysis; GAPDH served as the internal control. (B-D) Immunofluorescence staining of (B) myosin IIa (green), (C) MuRF1 (green), and (D) Atrogin-1 (green) in differentiated C2C12 myotubes (200× original magnification); scale bar=50 μm. Nuclei were counterstained with DAPI (blue). Data are presented as mean ± SEM from three independent experiments. * p <0.05, ** p <0.01 vs. the PA group.
    Signals For Murf1, supplied by ECM Biosciences, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/c+terminal+region/MuRF1+(C-terminal+region)/pmc13534901-93-22-26
    Average 95 stars, based on 1 article reviews
    signals for murf1 - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    86
    Azenta c terminal p2 l2 s2 e1 e2 dyw region
    Maslinic acid modulates atrophy-related marker expression in palmitic acid-treated C2C12 myotubes. Differentiated C2C12 myotubes were treated with MA (0-10 μM) and then challenged with PA (0.4 mM) under lipotoxic stress conditions. (A) Protein expression of myosin IIa, <t>MuRF1,</t> and Atrogin-1 was determined by Western blot analysis; GAPDH served as the internal control. (B-D) Immunofluorescence staining of (B) myosin IIa (green), (C) MuRF1 (green), and (D) Atrogin-1 (green) in differentiated C2C12 myotubes (200× original magnification); scale bar=50 μm. Nuclei were counterstained with DAPI (blue). Data are presented as mean ± SEM from three independent experiments. * p <0.05, ** p <0.01 vs. the PA group.
    C Terminal P2 L2 S2 E1 E2 Dyw Region, supplied by Azenta, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/c+terminal+region/dna+fragment/pm42045200-249-5-27
    Average 86 stars, based on 1 article reviews
    c terminal p2 l2 s2 e1 e2 dyw region - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    93
    ECM Biosciences anti arp2
    Maslinic acid modulates atrophy-related marker expression in palmitic acid-treated C2C12 myotubes. Differentiated C2C12 myotubes were treated with MA (0-10 μM) and then challenged with PA (0.4 mM) under lipotoxic stress conditions. (A) Protein expression of myosin IIa, <t>MuRF1,</t> and Atrogin-1 was determined by Western blot analysis; GAPDH served as the internal control. (B-D) Immunofluorescence staining of (B) myosin IIa (green), (C) MuRF1 (green), and (D) Atrogin-1 (green) in differentiated C2C12 myotubes (200× original magnification); scale bar=50 μm. Nuclei were counterstained with DAPI (blue). Data are presented as mean ± SEM from three independent experiments. * p <0.05, ** p <0.01 vs. the PA group.
    Anti Arp2, supplied by ECM Biosciences, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/c+terminal+region/Arp2+(C-terminal+region)/pmc13047250-48-4-13
    Average 93 stars, based on 1 article reviews
    anti arp2 - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    93
    ECM Biosciences anti arpc1b
    Maslinic acid modulates atrophy-related marker expression in palmitic acid-treated C2C12 myotubes. Differentiated C2C12 myotubes were treated with MA (0-10 μM) and then challenged with PA (0.4 mM) under lipotoxic stress conditions. (A) Protein expression of myosin IIa, <t>MuRF1,</t> and Atrogin-1 was determined by Western blot analysis; GAPDH served as the internal control. (B-D) Immunofluorescence staining of (B) myosin IIa (green), (C) MuRF1 (green), and (D) Atrogin-1 (green) in differentiated C2C12 myotubes (200× original magnification); scale bar=50 μm. Nuclei were counterstained with DAPI (blue). Data are presented as mean ± SEM from three independent experiments. * p <0.05, ** p <0.01 vs. the PA group.
    Anti Arpc1b, supplied by ECM Biosciences, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/c+terminal+region/Arpc1b%2Fp41-Arc+(C-terminal+region)/pmc13047250-48-9-13
    Average 93 stars, based on 1 article reviews
    anti arpc1b - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    93
    ECM Biosciences anti arp3
    Maslinic acid modulates atrophy-related marker expression in palmitic acid-treated C2C12 myotubes. Differentiated C2C12 myotubes were treated with MA (0-10 μM) and then challenged with PA (0.4 mM) under lipotoxic stress conditions. (A) Protein expression of myosin IIa, <t>MuRF1,</t> and Atrogin-1 was determined by Western blot analysis; GAPDH served as the internal control. (B-D) Immunofluorescence staining of (B) myosin IIa (green), (C) MuRF1 (green), and (D) Atrogin-1 (green) in differentiated C2C12 myotubes (200× original magnification); scale bar=50 μm. Nuclei were counterstained with DAPI (blue). Data are presented as mean ± SEM from three independent experiments. * p <0.05, ** p <0.01 vs. the PA group.
    Anti Arp3, supplied by ECM Biosciences, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/c+terminal+region/Arp3+(C-terminal+region)/pmc13047250-48-6-13
    Average 93 stars, based on 1 article reviews
    anti arp3 - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    95
    ECM Biosciences atrogin 1
    a. Schematic showing experimental approach to disrupt autophagy in the muscle of mice with genetically engineered KP −/− F PDAC tumors. b. Western blot assessing Atg7 protein in muscle tissue from 6-week-old control ( Pdx-1-P2A-FlpO; Trp53 Frt/Frt ; Ckm-Cre ) or Atg7 muscle knock-out mice ( Ckm-Cre ; Atg7 fl/fl : referred to as Atg7 mKO), without or with ( Pdx-1-P2A-FlpO; Kras FSF-G12D/+ ; Trp53 Frt/Frt ) KP −/− F PDAC as indicated ( n = 3). Also shown is western blot for Atg7 in pancreas tissue from control and Atg7 mKO mice with KP −/− F PDAC ( n = 5). c. Western blot for Atg7, Atg5, p62, Lc3B-I, and Lc3B-II in gastrocnemius muscle from 6-week-old control and Atg7 mKO mice with KP −/− F PDAC ( n = 2). Vinculin is blotted as a loading control. d. Gastrocnemius, quadriceps, and soleus skeletal muscle weights normalized to whole-body weights from 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated ( n = 14 control, n = 12 Atg7 mKO, n = 16 KP −/− F PDAC, and n = 11 Atg7 mKO KP −/− F PDAC). e. H&E staining of gastrocnemius muscle from 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated. f. Myofiber area quantification from histology shown in e. ( n = 230 control, n = 166 Atg7 mKO, n = 477 KP −/− F PDAC, and n = 186 Atg7 mKO KP −/− F PDAC from n = 4 mice for each group). g-l. Whole-body weight ( n = 14 control, n = 14 Atg7 mKO, n = 16 KP −/− F PDAC, and n = 14 Atg7 mKO KP −/− F PDAC, 6-week-old) (g), food intake ( n = 5) (h), blood glucose ( n = 9) (i), plasma insulin ( n = 7 control, n = 6 Atg7 mKO, n = 5 PDAC, and n = 5 Atg7 mKO KP −/− F PDAC) (j), liver weight ( n = 11 control, n = 12 Atg7 mKO, n = 15 KP −/− F PDAC, and n = 11 Atg7 mKO KP −/− F PDAC) (k), and perigonadal and subcutaneous ATs weights ( n = 14 control, n = 12 Atg7 mKO, n = 16 KP −/− F PDAC, and n = 11 Atg7 mKO KP −/− F PDAC) (l) normalized to whole-body weights of 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated. m. H&E staining of perigonadal AT from control and Atg7 mKO mice with KP −/− F PDAC. n. Pancreas tissue weights normalized to whole-body weights from 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated ( n = 11 control, n = 12 Atg7 mKO, n = 11 KP −/− F PDAC, and n = 12 Atg7 mKO KP −/− F PDAC). o. Gross images of pancreas from 6-week-old control and Atg7 mKO mice with KP −/− F PDAC as indicated ( n = 2). p. H&E staining of pancreas tissue from 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated. q. Survival of control mice with KP −/− F PDAC ( Pdx-1-P2A-FlpO; Kras FSF-G12D/+ ; Trp53 Frt/Frt , referred to here as KP −/− F PDAC), or the same mice with a Ckm-Cre and one ( Atg7 fl/+ ) or two ( Atg7 fl/fl ) Atg7 fl alleles as indicated ( n = 43 PDAC, n = 50 Atg7 fl/+ , and n = 82 Atg7 fl/fl ). r. Survival of control or Atg7 mKO mice following orthotopic implantation of murine KPC PDAC cells into pancreas ( n = 6). s. Survival analysis of control mice and mice with muscle-specific loss of function <t>of</t> <t>Atrogin-1</t> ( Atrogin-1 fl/fl ; Ckm-Cre: Atrogin-1 mLOF) following orthotopic pancreatic implantation of KPC PDAC cells ( n = 6). t. Survival analysis of control mice and mice with combined muscle-specific Atrogin-1 loss of function and Atg7 deletion ( Atrogin-1 mLOF; Atg7 mKO) following orthotopic KPC PDAC implantation ( n = 6). Both male and female mice were used in experiments. Statistical analyses were performed using one-way ANOVA with Tukey’s post hoc test for data in panels c-j and m-n. P-values on survival experiments were calculated with Gehan-Breslow-Wilcoxon test. Data are presented as mean ± S.D., and n denotes the number of mice analyzed. Scale bars: 100 μm.
    Atrogin 1, supplied by ECM Biosciences, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/c+terminal+region/MuRF1+(C-terminal+region)/bio_rxiv__64898__2026__02__27__708635-584-259-260
    Average 95 stars, based on 1 article reviews
    atrogin 1 - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    95
    ECM Biosciences murf1
    a. Schematic showing experimental approach to disrupt autophagy in the muscle of mice with genetically engineered KP −/− F PDAC tumors. b. Western blot assessing Atg7 protein in muscle tissue from 6-week-old control ( Pdx-1-P2A-FlpO; Trp53 Frt/Frt ; Ckm-Cre ) or Atg7 muscle knock-out mice ( Ckm-Cre ; Atg7 fl/fl : referred to as Atg7 mKO), without or with ( Pdx-1-P2A-FlpO; Kras FSF-G12D/+ ; Trp53 Frt/Frt ) KP −/− F PDAC as indicated ( n = 3). Also shown is western blot for Atg7 in pancreas tissue from control and Atg7 mKO mice with KP −/− F PDAC ( n = 5). c. Western blot for Atg7, Atg5, p62, Lc3B-I, and Lc3B-II in gastrocnemius muscle from 6-week-old control and Atg7 mKO mice with KP −/− F PDAC ( n = 2). Vinculin is blotted as a loading control. d. Gastrocnemius, quadriceps, and soleus skeletal muscle weights normalized to whole-body weights from 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated ( n = 14 control, n = 12 Atg7 mKO, n = 16 KP −/− F PDAC, and n = 11 Atg7 mKO KP −/− F PDAC). e. H&E staining of gastrocnemius muscle from 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated. f. Myofiber area quantification from histology shown in e. ( n = 230 control, n = 166 Atg7 mKO, n = 477 KP −/− F PDAC, and n = 186 Atg7 mKO KP −/− F PDAC from n = 4 mice for each group). g-l. Whole-body weight ( n = 14 control, n = 14 Atg7 mKO, n = 16 KP −/− F PDAC, and n = 14 Atg7 mKO KP −/− F PDAC, 6-week-old) (g), food intake ( n = 5) (h), blood glucose ( n = 9) (i), plasma insulin ( n = 7 control, n = 6 Atg7 mKO, n = 5 PDAC, and n = 5 Atg7 mKO KP −/− F PDAC) (j), liver weight ( n = 11 control, n = 12 Atg7 mKO, n = 15 KP −/− F PDAC, and n = 11 Atg7 mKO KP −/− F PDAC) (k), and perigonadal and subcutaneous ATs weights ( n = 14 control, n = 12 Atg7 mKO, n = 16 KP −/− F PDAC, and n = 11 Atg7 mKO KP −/− F PDAC) (l) normalized to whole-body weights of 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated. m. H&E staining of perigonadal AT from control and Atg7 mKO mice with KP −/− F PDAC. n. Pancreas tissue weights normalized to whole-body weights from 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated ( n = 11 control, n = 12 Atg7 mKO, n = 11 KP −/− F PDAC, and n = 12 Atg7 mKO KP −/− F PDAC). o. Gross images of pancreas from 6-week-old control and Atg7 mKO mice with KP −/− F PDAC as indicated ( n = 2). p. H&E staining of pancreas tissue from 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated. q. Survival of control mice with KP −/− F PDAC ( Pdx-1-P2A-FlpO; Kras FSF-G12D/+ ; Trp53 Frt/Frt , referred to here as KP −/− F PDAC), or the same mice with a Ckm-Cre and one ( Atg7 fl/+ ) or two ( Atg7 fl/fl ) Atg7 fl alleles as indicated ( n = 43 PDAC, n = 50 Atg7 fl/+ , and n = 82 Atg7 fl/fl ). r. Survival of control or Atg7 mKO mice following orthotopic implantation of murine KPC PDAC cells into pancreas ( n = 6). s. Survival analysis of control mice and mice with muscle-specific loss of function <t>of</t> <t>Atrogin-1</t> ( Atrogin-1 fl/fl ; Ckm-Cre: Atrogin-1 mLOF) following orthotopic pancreatic implantation of KPC PDAC cells ( n = 6). t. Survival analysis of control mice and mice with combined muscle-specific Atrogin-1 loss of function and Atg7 deletion ( Atrogin-1 mLOF; Atg7 mKO) following orthotopic KPC PDAC implantation ( n = 6). Both male and female mice were used in experiments. Statistical analyses were performed using one-way ANOVA with Tukey’s post hoc test for data in panels c-j and m-n. P-values on survival experiments were calculated with Gehan-Breslow-Wilcoxon test. Data are presented as mean ± S.D., and n denotes the number of mice analyzed. Scale bars: 100 μm.
    Murf1, supplied by ECM Biosciences, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/c+terminal+region/MuRF1+(C-terminal+region)/bio_rxiv__64898__2026__02__27__708635-584-254-255
    Average 95 stars, based on 1 article reviews
    murf1 - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    91
    Aviva Systems tdp 43
    a. Schematic showing experimental approach to disrupt autophagy in the muscle of mice with genetically engineered KP −/− F PDAC tumors. b. Western blot assessing Atg7 protein in muscle tissue from 6-week-old control ( Pdx-1-P2A-FlpO; Trp53 Frt/Frt ; Ckm-Cre ) or Atg7 muscle knock-out mice ( Ckm-Cre ; Atg7 fl/fl : referred to as Atg7 mKO), without or with ( Pdx-1-P2A-FlpO; Kras FSF-G12D/+ ; Trp53 Frt/Frt ) KP −/− F PDAC as indicated ( n = 3). Also shown is western blot for Atg7 in pancreas tissue from control and Atg7 mKO mice with KP −/− F PDAC ( n = 5). c. Western blot for Atg7, Atg5, p62, Lc3B-I, and Lc3B-II in gastrocnemius muscle from 6-week-old control and Atg7 mKO mice with KP −/− F PDAC ( n = 2). Vinculin is blotted as a loading control. d. Gastrocnemius, quadriceps, and soleus skeletal muscle weights normalized to whole-body weights from 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated ( n = 14 control, n = 12 Atg7 mKO, n = 16 KP −/− F PDAC, and n = 11 Atg7 mKO KP −/− F PDAC). e. H&E staining of gastrocnemius muscle from 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated. f. Myofiber area quantification from histology shown in e. ( n = 230 control, n = 166 Atg7 mKO, n = 477 KP −/− F PDAC, and n = 186 Atg7 mKO KP −/− F PDAC from n = 4 mice for each group). g-l. Whole-body weight ( n = 14 control, n = 14 Atg7 mKO, n = 16 KP −/− F PDAC, and n = 14 Atg7 mKO KP −/− F PDAC, 6-week-old) (g), food intake ( n = 5) (h), blood glucose ( n = 9) (i), plasma insulin ( n = 7 control, n = 6 Atg7 mKO, n = 5 PDAC, and n = 5 Atg7 mKO KP −/− F PDAC) (j), liver weight ( n = 11 control, n = 12 Atg7 mKO, n = 15 KP −/− F PDAC, and n = 11 Atg7 mKO KP −/− F PDAC) (k), and perigonadal and subcutaneous ATs weights ( n = 14 control, n = 12 Atg7 mKO, n = 16 KP −/− F PDAC, and n = 11 Atg7 mKO KP −/− F PDAC) (l) normalized to whole-body weights of 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated. m. H&E staining of perigonadal AT from control and Atg7 mKO mice with KP −/− F PDAC. n. Pancreas tissue weights normalized to whole-body weights from 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated ( n = 11 control, n = 12 Atg7 mKO, n = 11 KP −/− F PDAC, and n = 12 Atg7 mKO KP −/− F PDAC). o. Gross images of pancreas from 6-week-old control and Atg7 mKO mice with KP −/− F PDAC as indicated ( n = 2). p. H&E staining of pancreas tissue from 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated. q. Survival of control mice with KP −/− F PDAC ( Pdx-1-P2A-FlpO; Kras FSF-G12D/+ ; Trp53 Frt/Frt , referred to here as KP −/− F PDAC), or the same mice with a Ckm-Cre and one ( Atg7 fl/+ ) or two ( Atg7 fl/fl ) Atg7 fl alleles as indicated ( n = 43 PDAC, n = 50 Atg7 fl/+ , and n = 82 Atg7 fl/fl ). r. Survival of control or Atg7 mKO mice following orthotopic implantation of murine KPC PDAC cells into pancreas ( n = 6). s. Survival analysis of control mice and mice with muscle-specific loss of function <t>of</t> <t>Atrogin-1</t> ( Atrogin-1 fl/fl ; Ckm-Cre: Atrogin-1 mLOF) following orthotopic pancreatic implantation of KPC PDAC cells ( n = 6). t. Survival analysis of control mice and mice with combined muscle-specific Atrogin-1 loss of function and Atg7 deletion ( Atrogin-1 mLOF; Atg7 mKO) following orthotopic KPC PDAC implantation ( n = 6). Both male and female mice were used in experiments. Statistical analyses were performed using one-way ANOVA with Tukey’s post hoc test for data in panels c-j and m-n. P-values on survival experiments were calculated with Gehan-Breslow-Wilcoxon test. Data are presented as mean ± S.D., and n denotes the number of mice analyzed. Scale bars: 100 μm.
    Tdp 43, supplied by Aviva Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/c+terminal+region/TARDBP+antibody+-+C-terminal+region+(ARP38942_T100)/pm41691309-427-68-71
    Average 91 stars, based on 1 article reviews
    tdp 43 - by Bioz Stars, 2026-11
    91/100 stars
      Buy from Supplier

    Image Search Results


    Maslinic acid modulates atrophy-related marker expression in palmitic acid-treated C2C12 myotubes. Differentiated C2C12 myotubes were treated with MA (0-10 μM) and then challenged with PA (0.4 mM) under lipotoxic stress conditions. (A) Protein expression of myosin IIa, MuRF1, and Atrogin-1 was determined by Western blot analysis; GAPDH served as the internal control. (B-D) Immunofluorescence staining of (B) myosin IIa (green), (C) MuRF1 (green), and (D) Atrogin-1 (green) in differentiated C2C12 myotubes (200× original magnification); scale bar=50 μm. Nuclei were counterstained with DAPI (blue). Data are presented as mean ± SEM from three independent experiments. * p <0.05, ** p <0.01 vs. the PA group.

    Journal: Biomolecules & Therapeutics

    Article Title: Maslinic Acid Alleviates Obesity-Associated Skeletal Muscle Atrophy and Adipose Tissue Dysfunction in Obese Mice

    doi: 10.4062/biomolther.2026.072

    Figure Lengend Snippet: Maslinic acid modulates atrophy-related marker expression in palmitic acid-treated C2C12 myotubes. Differentiated C2C12 myotubes were treated with MA (0-10 μM) and then challenged with PA (0.4 mM) under lipotoxic stress conditions. (A) Protein expression of myosin IIa, MuRF1, and Atrogin-1 was determined by Western blot analysis; GAPDH served as the internal control. (B-D) Immunofluorescence staining of (B) myosin IIa (green), (C) MuRF1 (green), and (D) Atrogin-1 (green) in differentiated C2C12 myotubes (200× original magnification); scale bar=50 μm. Nuclei were counterstained with DAPI (blue). Data are presented as mean ± SEM from three independent experiments. * p <0.05, ** p <0.01 vs. the PA group.

    Article Snippet: The sections were incubated with primary antibodies (1:50) at 4°C overnight, followed by incubation with the corresponding secondary antibody for 1 h. Signals for MuRF1 (#MP3401; ECM Biosciences) and Atrogin-1 (ab168372; Abcam) were visualized using a DAB chromogenic substrate.

    Techniques: Marker, Expressing, Western Blot, Control, Immunofluorescence, Staining

    Maslinic acid modulates atrophy-related protein expression and GLUT4 expression in the skeletal muscle of obese mice. (A) Protein expression of pAKT, AKT, myosin IIa, MuRF1, and Atrogin-1 in gastrocnemius muscle was determined by Western blot analysis; GAPDH served as the internal control. (B) Immunofluorescence staining of GLUT4 (green) and (C) MuRF1 (green) in gastrocnemius muscle. (D) Immunohistochemical staining of MuRF1 (dark brown). (E) Immunofluorescence staining (red) and (F) immunohistochemical staining of Atrogin-1 (dark brown) in gastrocnemius muscle (100×original magnification); scale bar=50 μm. Nuclei in the immunofluorescence images were counterstained with DAPI (blue). Data are presented as mean ± SEM; n=12 per group. * p <0.05, ** p <0.01 vs. the HFD group.

    Journal: Biomolecules & Therapeutics

    Article Title: Maslinic Acid Alleviates Obesity-Associated Skeletal Muscle Atrophy and Adipose Tissue Dysfunction in Obese Mice

    doi: 10.4062/biomolther.2026.072

    Figure Lengend Snippet: Maslinic acid modulates atrophy-related protein expression and GLUT4 expression in the skeletal muscle of obese mice. (A) Protein expression of pAKT, AKT, myosin IIa, MuRF1, and Atrogin-1 in gastrocnemius muscle was determined by Western blot analysis; GAPDH served as the internal control. (B) Immunofluorescence staining of GLUT4 (green) and (C) MuRF1 (green) in gastrocnemius muscle. (D) Immunohistochemical staining of MuRF1 (dark brown). (E) Immunofluorescence staining (red) and (F) immunohistochemical staining of Atrogin-1 (dark brown) in gastrocnemius muscle (100×original magnification); scale bar=50 μm. Nuclei in the immunofluorescence images were counterstained with DAPI (blue). Data are presented as mean ± SEM; n=12 per group. * p <0.05, ** p <0.01 vs. the HFD group.

    Article Snippet: The sections were incubated with primary antibodies (1:50) at 4°C overnight, followed by incubation with the corresponding secondary antibody for 1 h. Signals for MuRF1 (#MP3401; ECM Biosciences) and Atrogin-1 (ab168372; Abcam) were visualized using a DAB chromogenic substrate.

    Techniques: Expressing, Western Blot, Control, Immunofluorescence, Staining, Immunohistochemical staining

    Proposed model summarizing the effects of maslinic acid on adipocyte metabolic dysfunction and skeletal muscle atrophic changes in obese mice. Maslinic acid (MA) reduced lipid accumulation and inflammation in adipose tissue, decreased M1 macrophage-associated marker expression, increased M2 macrophage-associated marker expression, and lowered TNF-α and IL-6 levels. In skeletal muscle and palmitic acid-treated C2C12 myotubes, MA increased AKT and FOXO1 phosphorylation and myosin IIa expression, while reducing MuRF1 and Atrogin-1 expression. MA was also associated with improved mitochondrial morphology and respiratory responses, increased mitofusin-2 expression, and reduced DRP1 phosphorylation. Collectively, these changes may contribute to the attenuation of obesity-associated skeletal muscle atrophic changes. Upward and downward arrows indicate increases and decreases, respectively.

    Journal: Biomolecules & Therapeutics

    Article Title: Maslinic Acid Alleviates Obesity-Associated Skeletal Muscle Atrophy and Adipose Tissue Dysfunction in Obese Mice

    doi: 10.4062/biomolther.2026.072

    Figure Lengend Snippet: Proposed model summarizing the effects of maslinic acid on adipocyte metabolic dysfunction and skeletal muscle atrophic changes in obese mice. Maslinic acid (MA) reduced lipid accumulation and inflammation in adipose tissue, decreased M1 macrophage-associated marker expression, increased M2 macrophage-associated marker expression, and lowered TNF-α and IL-6 levels. In skeletal muscle and palmitic acid-treated C2C12 myotubes, MA increased AKT and FOXO1 phosphorylation and myosin IIa expression, while reducing MuRF1 and Atrogin-1 expression. MA was also associated with improved mitochondrial morphology and respiratory responses, increased mitofusin-2 expression, and reduced DRP1 phosphorylation. Collectively, these changes may contribute to the attenuation of obesity-associated skeletal muscle atrophic changes. Upward and downward arrows indicate increases and decreases, respectively.

    Article Snippet: The sections were incubated with primary antibodies (1:50) at 4°C overnight, followed by incubation with the corresponding secondary antibody for 1 h. Signals for MuRF1 (#MP3401; ECM Biosciences) and Atrogin-1 (ab168372; Abcam) were visualized using a DAB chromogenic substrate.

    Techniques: Marker, Expressing, Phospho-proteomics

    a. Schematic showing experimental approach to disrupt autophagy in the muscle of mice with genetically engineered KP −/− F PDAC tumors. b. Western blot assessing Atg7 protein in muscle tissue from 6-week-old control ( Pdx-1-P2A-FlpO; Trp53 Frt/Frt ; Ckm-Cre ) or Atg7 muscle knock-out mice ( Ckm-Cre ; Atg7 fl/fl : referred to as Atg7 mKO), without or with ( Pdx-1-P2A-FlpO; Kras FSF-G12D/+ ; Trp53 Frt/Frt ) KP −/− F PDAC as indicated ( n = 3). Also shown is western blot for Atg7 in pancreas tissue from control and Atg7 mKO mice with KP −/− F PDAC ( n = 5). c. Western blot for Atg7, Atg5, p62, Lc3B-I, and Lc3B-II in gastrocnemius muscle from 6-week-old control and Atg7 mKO mice with KP −/− F PDAC ( n = 2). Vinculin is blotted as a loading control. d. Gastrocnemius, quadriceps, and soleus skeletal muscle weights normalized to whole-body weights from 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated ( n = 14 control, n = 12 Atg7 mKO, n = 16 KP −/− F PDAC, and n = 11 Atg7 mKO KP −/− F PDAC). e. H&E staining of gastrocnemius muscle from 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated. f. Myofiber area quantification from histology shown in e. ( n = 230 control, n = 166 Atg7 mKO, n = 477 KP −/− F PDAC, and n = 186 Atg7 mKO KP −/− F PDAC from n = 4 mice for each group). g-l. Whole-body weight ( n = 14 control, n = 14 Atg7 mKO, n = 16 KP −/− F PDAC, and n = 14 Atg7 mKO KP −/− F PDAC, 6-week-old) (g), food intake ( n = 5) (h), blood glucose ( n = 9) (i), plasma insulin ( n = 7 control, n = 6 Atg7 mKO, n = 5 PDAC, and n = 5 Atg7 mKO KP −/− F PDAC) (j), liver weight ( n = 11 control, n = 12 Atg7 mKO, n = 15 KP −/− F PDAC, and n = 11 Atg7 mKO KP −/− F PDAC) (k), and perigonadal and subcutaneous ATs weights ( n = 14 control, n = 12 Atg7 mKO, n = 16 KP −/− F PDAC, and n = 11 Atg7 mKO KP −/− F PDAC) (l) normalized to whole-body weights of 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated. m. H&E staining of perigonadal AT from control and Atg7 mKO mice with KP −/− F PDAC. n. Pancreas tissue weights normalized to whole-body weights from 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated ( n = 11 control, n = 12 Atg7 mKO, n = 11 KP −/− F PDAC, and n = 12 Atg7 mKO KP −/− F PDAC). o. Gross images of pancreas from 6-week-old control and Atg7 mKO mice with KP −/− F PDAC as indicated ( n = 2). p. H&E staining of pancreas tissue from 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated. q. Survival of control mice with KP −/− F PDAC ( Pdx-1-P2A-FlpO; Kras FSF-G12D/+ ; Trp53 Frt/Frt , referred to here as KP −/− F PDAC), or the same mice with a Ckm-Cre and one ( Atg7 fl/+ ) or two ( Atg7 fl/fl ) Atg7 fl alleles as indicated ( n = 43 PDAC, n = 50 Atg7 fl/+ , and n = 82 Atg7 fl/fl ). r. Survival of control or Atg7 mKO mice following orthotopic implantation of murine KPC PDAC cells into pancreas ( n = 6). s. Survival analysis of control mice and mice with muscle-specific loss of function of Atrogin-1 ( Atrogin-1 fl/fl ; Ckm-Cre: Atrogin-1 mLOF) following orthotopic pancreatic implantation of KPC PDAC cells ( n = 6). t. Survival analysis of control mice and mice with combined muscle-specific Atrogin-1 loss of function and Atg7 deletion ( Atrogin-1 mLOF; Atg7 mKO) following orthotopic KPC PDAC implantation ( n = 6). Both male and female mice were used in experiments. Statistical analyses were performed using one-way ANOVA with Tukey’s post hoc test for data in panels c-j and m-n. P-values on survival experiments were calculated with Gehan-Breslow-Wilcoxon test. Data are presented as mean ± S.D., and n denotes the number of mice analyzed. Scale bars: 100 μm.

    Journal: bioRxiv

    Article Title: Pancreatic cancer-associated organ dysfunction promotes muscle autophagy and contributes to peripheral tissue wasting

    doi: 10.64898/2026.02.27.708635

    Figure Lengend Snippet: a. Schematic showing experimental approach to disrupt autophagy in the muscle of mice with genetically engineered KP −/− F PDAC tumors. b. Western blot assessing Atg7 protein in muscle tissue from 6-week-old control ( Pdx-1-P2A-FlpO; Trp53 Frt/Frt ; Ckm-Cre ) or Atg7 muscle knock-out mice ( Ckm-Cre ; Atg7 fl/fl : referred to as Atg7 mKO), without or with ( Pdx-1-P2A-FlpO; Kras FSF-G12D/+ ; Trp53 Frt/Frt ) KP −/− F PDAC as indicated ( n = 3). Also shown is western blot for Atg7 in pancreas tissue from control and Atg7 mKO mice with KP −/− F PDAC ( n = 5). c. Western blot for Atg7, Atg5, p62, Lc3B-I, and Lc3B-II in gastrocnemius muscle from 6-week-old control and Atg7 mKO mice with KP −/− F PDAC ( n = 2). Vinculin is blotted as a loading control. d. Gastrocnemius, quadriceps, and soleus skeletal muscle weights normalized to whole-body weights from 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated ( n = 14 control, n = 12 Atg7 mKO, n = 16 KP −/− F PDAC, and n = 11 Atg7 mKO KP −/− F PDAC). e. H&E staining of gastrocnemius muscle from 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated. f. Myofiber area quantification from histology shown in e. ( n = 230 control, n = 166 Atg7 mKO, n = 477 KP −/− F PDAC, and n = 186 Atg7 mKO KP −/− F PDAC from n = 4 mice for each group). g-l. Whole-body weight ( n = 14 control, n = 14 Atg7 mKO, n = 16 KP −/− F PDAC, and n = 14 Atg7 mKO KP −/− F PDAC, 6-week-old) (g), food intake ( n = 5) (h), blood glucose ( n = 9) (i), plasma insulin ( n = 7 control, n = 6 Atg7 mKO, n = 5 PDAC, and n = 5 Atg7 mKO KP −/− F PDAC) (j), liver weight ( n = 11 control, n = 12 Atg7 mKO, n = 15 KP −/− F PDAC, and n = 11 Atg7 mKO KP −/− F PDAC) (k), and perigonadal and subcutaneous ATs weights ( n = 14 control, n = 12 Atg7 mKO, n = 16 KP −/− F PDAC, and n = 11 Atg7 mKO KP −/− F PDAC) (l) normalized to whole-body weights of 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated. m. H&E staining of perigonadal AT from control and Atg7 mKO mice with KP −/− F PDAC. n. Pancreas tissue weights normalized to whole-body weights from 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated ( n = 11 control, n = 12 Atg7 mKO, n = 11 KP −/− F PDAC, and n = 12 Atg7 mKO KP −/− F PDAC). o. Gross images of pancreas from 6-week-old control and Atg7 mKO mice with KP −/− F PDAC as indicated ( n = 2). p. H&E staining of pancreas tissue from 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated. q. Survival of control mice with KP −/− F PDAC ( Pdx-1-P2A-FlpO; Kras FSF-G12D/+ ; Trp53 Frt/Frt , referred to here as KP −/− F PDAC), or the same mice with a Ckm-Cre and one ( Atg7 fl/+ ) or two ( Atg7 fl/fl ) Atg7 fl alleles as indicated ( n = 43 PDAC, n = 50 Atg7 fl/+ , and n = 82 Atg7 fl/fl ). r. Survival of control or Atg7 mKO mice following orthotopic implantation of murine KPC PDAC cells into pancreas ( n = 6). s. Survival analysis of control mice and mice with muscle-specific loss of function of Atrogin-1 ( Atrogin-1 fl/fl ; Ckm-Cre: Atrogin-1 mLOF) following orthotopic pancreatic implantation of KPC PDAC cells ( n = 6). t. Survival analysis of control mice and mice with combined muscle-specific Atrogin-1 loss of function and Atg7 deletion ( Atrogin-1 mLOF; Atg7 mKO) following orthotopic KPC PDAC implantation ( n = 6). Both male and female mice were used in experiments. Statistical analyses were performed using one-way ANOVA with Tukey’s post hoc test for data in panels c-j and m-n. P-values on survival experiments were calculated with Gehan-Breslow-Wilcoxon test. Data are presented as mean ± S.D., and n denotes the number of mice analyzed. Scale bars: 100 μm.

    Article Snippet: Membranes were blocked in 5% non-fat milk in TBS-T and probed overnight at 4 °C with the appropriate antibody diluted in 5% BSA in TBS-T. Primary antibodies were used including Vinculin (Cell Signaling Technology, 13901, clone E1E9V, 1:1,000), PRSS2 (Trypsin, Abclonal, A19275, 1:1,000), PNLIP (Pancreatic lipase, 11209-1AP-Proteintech, 1:1,000), Elastase (Abcam, ab21590, 1:1,000 dilution), α-Amylase (Santa Cruz, G10 clone-sc46657, 1:1,000), LC3B (Cell Signaling Technology, E7X4S, 1:1,000), phospho-ribosomal protein S6 Ser 235/236 (Cell Signaling Technology, 4858, 1/1,000), ribosomal protein S6 (Cell Signaling Technology, 2217, 1:1,000), phospho-p70 S6 kinase Thr389 (Cell Signaling Technology, 9205, 1:1,000), p70 S6 kinase (Cell Signaling Technology, 9202, 1:1,000), phospho-AMPK (Cell Signaling Technology, 2535, 1:1,000), AMPK (Cell Signaling Technology, 2532, 1:1,000), FOXO1 (Abclonal, A13862, 1:1,000), FOXO3A (Abclonal, A0102, 1:1,000), Anti-HA (Millipore-Sigma, 11867423001, 1:1,000), Cathepsin B (Cell Signaling Technology, D1C7Y, 1:1,000), Cathepsin L (R&D Systems, AF1515-SP, 1:1,000), ULK1 (Cell Signaling Technology, D8H5, 1:1,000), ATG5 (Cell Signaling Technology, D5F5U, 1:1,000), ATG7 (Sigma-Aldrich, A2856, 1:1,000), Puromycin (Sigma, MABE343, 1:10,000), EIF3F (Fortis Life Sciences, A303-005A-T, 1:1,000), Proteasome 20S Alpha7 subunit (ENZO Life sciences, BML-PW8110-0025, 1:1,000), Proteasome 19S Rpt3/S6b subunit (ENZO Life sciences, BML-PW8765-0025, 1:1,000), UBCJ2 (ENZO Life sciences, ENZ-ABS840-0100, 1:5,000), BNIP3 (Abcam, ab109362, 1:1,000), phosho-Acetyl-CoA Carboxylase I (S79) (Cell Signaling Technology, 6571S, 1:1,000), Acetyl-CoA Carboxylase I (Cell Signaling Technology, 3661S, 1:1,000), ATG3 (Cell Signaling Technology, 3415, 1:1,000), Calpain (Thermo Scientific, 9A4H8D3, 1:1,000), Lamp1 (Cell Signaling Technology, C54H11, 1:1,000), Lamp2 (Santa Cruz, H4B4, sc-18822, 1:1,000), Catalase (Cell Signaling Technology, D4P7B, 12980S, 1:1,000), Histone H3 (Cell Signaling Technology, D1H2, 4499T, 1:1,000), Cox IV (Cell Signaling Technology, 3E11, 4850T, 1:1,000), MuRF1 (ECM Biosciences, MP3401, 1:1,000), Atrogin-1 (ECM Biosciences, A2041P, 1:1,000).

    Techniques: Western Blot, Control, Knock-Out, Staining, Clinical Proteomics